http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie sets UK price for ovarian cancer drug ELAHERE equal to US rate
-
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
-
AbbVie submits FDA application for parkinson's drug tavapadon
-
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
-
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
-
AbbVie Declares Quarterly Dividend
-
AbbVie reports outpatient monitoring results for lymphoma drug
-
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lym
-
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
-
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
-
AbbVie to acquire depression therapy from Gilgamesh for up to $1.2 billion
-
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
-
AbbVie reports positive phase 3 trial results for alopecia areata drug
-
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
-
AbbVie completes acquisition of Capstan Therapeutics
-
AbbVie Completes Acquisition of Capstan Therapeutics
-
SkinMedica® Unveils Its Newest Hydration Hero
-
AbbVie invests $195 million in US manufacturing facility expansion
-
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
-
Get Ready, JUVÉDERM® Day is Calling!
-
AbbVie Reports Second-Quarter 2025 Financial Results
-
AbbVie drug shows promise for severe hair loss condition
-
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
-
AbbVie seeks FDA approval for VENCLEXTA-acalabrutinib combination
-
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
-
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
-
AbbVie licenses cancer drug ISB 2001 from IGI for up to $1.925 billion
-
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
-
AbbVie licenses multiple myeloma drug from IGI for $700 million upfront
-
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
-
AbbVie (ABBV) to Acquire Capstan Therapeutics for $2.1 Billion
-
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
-
AbbVie (ABBV) Announces FDA's Acceptance of Allergan's Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM
-
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
-
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
-
AbbVie Declares Quarterly Dividend
-
AbbVie (ABBV) Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
-
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
-
AbbVie (ABBV) Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
-
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
-
AbbVie (ABBV): U.S. FDA Approves Expanded Indication for MAVYRET as First and Only Treatment for People with Acute Hepatitis C Virus
-
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
-
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
-
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
-
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
-
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
-
AbbVie (ABBV) Announces FDA Approval of EMRELIS for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer With High c-Met Protein Overexpression
-
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
-
AbbVie (ABBV) and ADARx Pharmaceuticals Enter Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
-
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
